J&J Enters Global License and Development Agreement with Pipeline Therapeutics for all Indications of PIPE-307
J&J's Janssen Pharmaceutica NV collaborates with Pipeline Therapeutics in a $50 million licensing deal for oral MS drug PIPE-307, with potential earnings of up to $1 billion for Pipeline.
Johnson & Johnson's Janssen Pharmaceutica NV has entered a $50 million upfront licensing agreement with Pipeline Therapeutics for an oral multiple sclerosis (MS) drug, PIPE-307, which has the potential to bring in up to $1 billion for the biotech company. PIPE-307, a muscarinic M1 receptor antagonist, has completed two phase 1 trials in healthy patients and is cleared for clinical development in relapsing-remitting MS patients.
Under the agreement, Janssen will obtain a worldwide license for PIPE-307's research, development, and commercialization in all potential indications, while Pipeline will retain the right to advance the therapy through the mid-stage MS trial.
In addition to the upfront payment, Pipeline will receive a $25 million equity payment from Johnson & Johnson Innovation and another $25 million from existing investors, with the possibility of $1 billion in clinical, regulatory, and commercial milestones, plus royalties if PIPE-307 proves successful.
Reference: J&J opens the valve on $50M MS partnership with Pipeline. April 17, 2023 / FierceBiotech
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
